BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2735696)

  • 1. Cyclosporine in Behçet's disease resistant to conventional therapy.
    Caspers-Velu LE; Decaux G; Libert J
    Ann Ophthalmol; 1989 Mar; 21(3):111-6, 118. PubMed ID: 2735696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of cyclosporin-a in the treatment of Behçet's disease.
    Atmaca LS; Batioğlu F
    Ophthalmic Surg; 1994 May; 25(5):321-7. PubMed ID: 8058265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Behçet's disease: a study of 20 cases].
    Jacobs K; Vrijghem JC; Linsen C; Leys A
    Bull Soc Belge Ophtalmol; 1989; 230():85-93. PubMed ID: 2488438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
    Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
    Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome.
    BenEzra D; Cohen E; Chajek T; Friedman G; Pizanti S; de Courten C; Harris W
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):136-43. PubMed ID: 3381269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of the ocular form of Behçet disease with cyclosporin A].
    Pahlitzsch T; Wyrobisch W; Kämpe C; Wiederholt M
    Klin Monbl Augenheilkd; 1990 Jun; 196(6):466-9. PubMed ID: 2376943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intravenous corticosteroid megadose treatment in ocular Behçet disease].
    Postelmans L; Verougstraete C; Libert J; Efira A; Caspers-Velu L
    Bull Soc Belge Ophtalmol; 1996; 262():95-103. PubMed ID: 9376926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal tears associated with panuveitis and Behçet's disease.
    Akova YA; Yilmaz G; Aydin P
    Ophthalmic Surg Lasers; 1999; 30(9):762-5. PubMed ID: 10574500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ocular prognosis in Behçet's disease].
    Cochereau-Massin I; Wechsler B; Le Hoang P; Le Thi Huong Du; Girard B; Rousselie F; Godeau P
    J Fr Ophtalmol; 1992; 15(5):343-7. PubMed ID: 1430813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
    Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
    Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
    Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
    Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
    Tabbara KF; Al-Hemidan AI
    Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy.
    Prummel MF; Mourits MP; Berghout A; Krenning EP; van der Gaag R; Koornneef L; Wiersinga WM
    N Engl J Med; 1989 Nov; 321(20):1353-9. PubMed ID: 2519530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of cyclophosphamide and colchicine treatment in Behçet's disease.
    Kazokoglu H; Saatçi O; Cuhadaroglu H; Eldem B
    Ann Ophthalmol; 1991 Apr; 23(4):148-51. PubMed ID: 2064258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
    Keino H; Okada AA; Watanabe T; Taki W
    Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunosuppressive therapy of Behcet's syndrome. Long term follow-up evaluation (author's transl)].
    Bonnet M
    J Fr Ophtalmol; 1981; 4(6-7):455-64. PubMed ID: 7299062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
    Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
    Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
    Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunosuppressive agents and Behçet's syndrome: critical analysis of results].
    Bonamour G; Bonnet M
    Adv Ophthalmol; 1978; 36():118-29. PubMed ID: 665399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.